This article appeared in LinkedIn Pulse on October 2, 2023
A Food and Drug Administration advisory panel’s decision to remove nasal decongestants containing phenylephrine from store shelves across the nation sent shockwaves across the healthcare spectrum. Phenylephrine, which is in more than 250 products worth nearly $1.8 billion in sales in 2022 and is used by millions to relieve symptoms of some of the most common illnesses, was found by the FDA panel to have no discernible effect.
U.S. consumers expect that FDA-approved medications are safe and effective. Medications that fail to deliver on their clinical claims should not be on the market.
Read more, here.